WEEI>On Demand>>OMF - Jay Quinn, 53, lung cancer, with Dr. Geoffrey Shapiro, director, Early Drug Development Center, Dana-Farber

OMF - Jay Quinn, 53, lung cancer, with Dr. Geoffrey Shapiro, director, Early Drug Development Center, Dana-Farber

Aug 30, 2016|

Jay is a lifelong non-smoker who developed a very aggressive type of lung cancer called NUT midline. It was very difficult to diagnosis. He needed molecular testing. He initially received chemotherapy. He came to Dana-Farber to try a new cancer drug on a clinical trial. He began the study in August 2015 and his disease has improved dramatically. It's a very complex, difficult treatment even requiring self-injections daily for 2 out of 3 weeks, but so far, it's working to keep his cancer at bay. He is a great example of the great results from the Early Drug Development Center at Dana-Farber. Jay Quinn loves baseball and has previously participated in training camp down in Florida despite having side effects related to treatment. He has a wife and a son and daughter. She is a student at Mass College of Art. Jay Quinn is disabled now but worked as a beer distributor. Dr. Shapiro directs the Early Drug Development Center – he is in charge of early or phase 1 trials of drugs being given to humans for the first time. He knows a lot about the very newest drug compounds, most of them coming from pharmaceutical companies, for different types of cancers.

You Might Like

Transcript - Not for consumer use. Robot overlords only. Will not be accurate.

Lets me judge. 53 from Berkeley is doctor doctor Jeffrey Shapiro. I. Of lung cancer how does that happened. Do you know now. I you know it's actually now lung cancers and well it's not Sonoma very rare. Form of cancer. Doctor Shapiro probably on William throw the yesterday Jane at the very rare cancer. The name comes from the protein that defines its probably not protein. And it's called not middling carcinoma and often looks like lung cancer and is often misdiagnosed that weighing. But it's a very aggressive cancer can come on very abruptly which is what happened today in early 2000. Fifteen. And often often as we said as an aside is misdiagnosed. 2015. With. Sort of the abrupt onset of problems with his liver. And how to misdiagnosis of a lung cancer but it's spread to deliver and began to get through chemotherapy for a. And luckily. I responded to chemotherapy. Once the chemo. Stopped responding. I immediately switched over to a clinical trial phase one clinical trial here Dana Farber. That was last August 20 side and on that trial since. And with. In over the course of the year might primary tumor has shrunk. 43 point 1% right so it's it's really done well for me. The side effects. I mean my body's. Sensitive to the drug. But so's my tumors I'll take that trade up any day. And down. Through jays are real Dana Farber story. So that diseases actually described by one of our pathologist who works at the Dana Farber Brigham doctor Chris French. And when we reviewed the pathology. Doctor French had developed the tools to be able to do to to diagnose this rare disease. And recognize that that was like these two lines. And as so it's up pointy he came to us for a consultation. He had. A response to the chemotherapy but the tumor was by no means eradicated. And at that point additionally. In our chemistry group. There were doctors that we're working on. I drugs that would attack the major proteins that defines this disease through the the protein that's not protein compares with a second protein caught up Romo domain protein. And our chemical biology group was developing drugs that block from it means. And I we've this is the clinical trial that entered that this drug was developed at the Dana Farber. Got a little bit of help from a startup company. And then we were able to get it into clinical trial in our only drug development center at the arbor so what does that our year anniversary. OJ started to study in August on August 20 2015. Correct. I'm he gets the drug gone by its sub cutaneous injection. Two weeks of every three and and now we do that because that we feel that we get better drug levels to the body with the injections. And say if it was formulated with in the world hill. And and it hasn't hasn't been done and hasn't been. Totally easy I think it's probably a little birdies here and chemotherapy. But the drug can lower the platelet count and of course there are a little bit of reactions where the injections to her and but to all this she's maintained a great spirit and dad's been able to play ball. Out of it that's an assault incredibly happy. And think he's myself and we want a virus. I wanna ask camera heroes and in the clinic on this let's go to friends again. I did. I've had incredible support from friends family teammates coworkers. People who Dana that. One of the you know. One of the baseball leagues I play and go find the page about can be finances and other wind did a fund raiser unbeknownst to me. Some confidence again for the first time ever come in January and. You get hurt did you I didn't Eric technical know how fortunate when it platelets that low but he'll play anyway you know I have to. And those guys do so whenever I do need to really point out though Jay's case roasted them because initially on the drug the tumors did not. Stable but it really wasn't a shrinking it's very interesting on some of our new molecular therapies the responses come late. And so it wasn't until we were on for many months that geez tumors began to shrink and we've been very gratified. That the primary amounts in the lung is down I said about between forty and 50%. There's no recurrence of any disease and liver. And also to speak to jays are Alex we did obvious that happens then this past week so he was playing ball right you got out. Car and he the I have someone steadiness I had some blurred vision. And the we ended up doing a brain MRI and my cancer has them metastasized in my brain so I have twelve reasons in my brain. And I've been receiving hold green radiation treatment for the last. While I've received nine out of ten treatment so far. The problem with some of our new drugs they don't often cross what we call them right let brain barrier. And they don't protect the brain from cancer so. We are radiating and you see alleles doing he looks and oh yeah actually doing very nicely and we're hoping to be back on the body to run a little bit later this week it's that you're it's just a setback you know and it's on the candidates and great really looking ahead you're at a great place. Then they've got all the cutting edge technology. And you couldn't be in a better place and we wish the best of luck too hopeful really do thank you very much in Asia doctor thanks guys from Chicago is an example Logitech.

News & Analysis